Insider Trading March 17, 2026

Director Richard Buchholz Adds 1,000 Shares of Shoulder Innovations; Company Posts Q4 Revenue Beat

Insider purchase coincides with recent stock momentum and analyst price-target increases after a quarterly revenue beat

By Priya Menon SI
Director Richard Buchholz Adds 1,000 Shares of Shoulder Innovations; Company Posts Q4 Revenue Beat
SI

Shoulder Innovations Inc. director Richard Buchholz purchased 1,000 shares on March 13, 2026, at $14.84 per share. The trade occurs after the stock climbed 16% over the prior week to $15.12. The company reported strong fourth-quarter 2025 revenue growth but remained unprofitable, while two firms raised price targets and maintained Buy ratings.

Key Points

  • Director Richard Buchholz purchased 1,000 shares at $14.84 on March 13, 2026, totaling $14,840 and now directly owns 13,666 shares.
  • The stock rose 16% over the prior week and was trading at $15.12 at the time of the report.
  • Shoulder Innovations reported Q4 2025 revenue of $14.4 million, a 65% year-over-year increase, but recorded a net loss of $7.8 million; Jefferies and BTIG raised price targets and maintained Buy ratings.

Shoulder Innovations Inc. (NASDAQ:SI) recorded an insider buy on March 13, 2026 when director Richard Buchholz acquired 1,000 shares of the companys common stock at $14.84 per share, for a transaction totaling $14,840.

Following the purchase, Buchholz directly holds 13,666 shares of Shoulder Innovations. The acquisition took place as the shares showed notable recent momentum, gaining 16% over the previous week and trading at $15.12 at the time of the report.

Independent analysis referenced in company reporting indicates the stock appears overvalued relative to its Fair Value. The valuation observation sits alongside a set of operational and market developments that investors may weigh as they assess the name.


Quarterly results and analyst responses

Shoulder Innovations posted fourth-quarter 2025 revenue of $14.4 million, a 65% increase year over year. Despite the revenue gain, the company reported a net loss of $7.8 million for the quarter.

Analyst reaction has been positive on the sales beat. Jefferies raised its price target for Shoulder Innovations to $21.00 from $20.00 and kept a Buy rating, citing sales that exceeded the consensus estimate of $12.8 million. BTIG likewise raised its price target to $24 from $23 and maintained a Buy rating, noting that revenue surpassed both their internal estimate of $12.6 million and consensus expectations.

Loss per share for the period was $0.38, compared with BTIGs estimate of a $0.36 loss and the consensus estimate of a $0.39 loss.

Company commentary and analyst notes attributed the stronger top-line performance to continued growth in implant utilization and the adoption of the companys products by new surgeons, factors cited as contributors to the quarter's revenue outperformance.


What this means for stakeholders

  • Insider buying: A director-level purchase increases a senior insiders direct stake to 13,666 shares.
  • Market reaction: The stock has moved higher in the short term, with a 16% gain over the last week to $15.12.
  • Operational results: Revenue expanded materially year over year, but the company remains unprofitable on a net-loss basis.

The combination of an insider purchase, a near-term share-price advance, a revenue beat, and analyst price-target raises frames the current public narrative around Shoulder Innovations, while valuation and profitability remain active data points for market participants.

Risks

  • The company reported a net loss of $7.8 million in Q4 2025, highlighting ongoing unprofitability that could affect future cash flow and financing needs - impacts healthcare and small-cap equity investors.
  • Independent analysis indicated the stock appears overvalued relative to its Fair Value, introducing valuation risk for investors in the medical-device sector and small-cap markets.
  • Earnings per share came in at a loss of $0.38, which differed slightly from analyst estimates and consensus, creating uncertainty around near-term profitability metrics relevant to analysts and investors following the healthcare equipment subsector.

More from Insider Trading

Navitas CFO Sells $1.06M of NVTS Stock Amid Transition and Product Announcements Mar 17, 2026 Astera Labs Director Disposes $325,000 in Stock as Company Posts Strong Q4 Results Mar 17, 2026 GeneDx CEO Sells $1.32M in WGS Stock to Meet RSU Tax Withholding Mar 17, 2026 PACS Group COO Sells $1.24M in Shares as Stock Trades Well Above Analyst Targets Mar 17, 2026 GeneDx CFO Disposes $438K in Stock Following Zero-Strike Option Exercise Mar 17, 2026